|  |
| --- |
| **2020 Taipei International Breast Cancer Symposium**7F, Taipei Nangang Exhibition Center, Hall 2 **Sat.**, November **7**, 2020 |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| 08:15-08:20 | Opening Remarks | Ling-Ming Tseng |
| 08:20-08:30 | Shih-Chung Chen |
| **Progress and Challenge** |
| 08:30-09:10 | Lessons learned in the treatment of breast cancer over the past five decades | Gabriel Hortobagyi | Ling-Ming Tseng |
| **Targeted Therapy 1**  |
| 09:10-09:15 | Case presentation, and vote | Jiun-I Lai |
| 09:15-09:45 | Use of Tyrosine Kinase Inhibitors in the treatment of HER2-positive breast cancer | Adam Brufsky | Hwei-Chung Wang |
| 09:45-10:15 | The role of PI3K inhibitor in HR+, HER2- advanced breast cancer and how to optimize the treatment | Ingrid Mayer | Tsu-Yi Chao |
| 10:15-10:40 | Panel discussion | Adam Brufsky / Ingrid Mayer/Wen-Ling Kuo Chih-Chiang Hung /Ying-Wen Su |
| 10:40-11:00 | Coffee Break |
| 11:00-11:30 | PARP inhibitors and immune checkpoint therapy on breast cancer | Mien-Chie Hung | King-Jen Chang Hsien-Tang Yeh |
| 11:30-12:00 | Ethnic difference in breast cancer treatment | Hiroji Iwata | Shyr-Ming Sheen-Chen |
| 12:00-12:30 | Cracking the genetic codes to unlock treatment options: a lesson from CGP on real-world cases | Chien-Feng Li | Fang-Ming Chen |
| **I/O and Chemotherapy** |
| 12:30-13:10 | Luncheon SymposiumCombination strategies of in Metastatic TNBC | Ming-Shen Dai | Hsien-Kun Chang |
| 13:10-13:20 | Break |
| 13:20-13:25 | Case presentation, and vote | Yi-Fang Tsai |
| 13:25-13:55 | Raise the bar higher: evolving treatment landscape in neoadjuvant TNBC with immunotherapy | Ming-Shen Dai | Jyh-Cherng Yu |
| 13:55-14:25 | Future roles of immune checkpoint inhibitors in breast cancer treatment- evolving integration from metastatic to peri-operative treatments | Chun-Yu Liu | Ming-Feng Hou |
| 14:25-14:55 | The transforming advancement in mBC treatment in 2020  | Peter Schmid | Yen-Shen Lu |
| 14:55-15:15 | Panel discussion | Ming-Shen Dai / Chun-Yu LiuPeter Schmid / Wen-Hung KuoLiang-Chih Liu / Dwan-Ying Chang |
| 15:15-15:35 | Coffee Break |
| **Targeted Therapy II**  |
| 15:35-15:40 | Case presentation, and vote | Chien-Ting Liu |
| 15:40-16:10 | HER2 EBC treatment overview | Luca Gianni | Chiun-Sheng Huang |
| 16:10-16:40 | Bringing biosimilars to life: clinical experience sharing | Marc Thill | Su-Shun Lo |
| 16:40-17:10 | Two decades after BRCA discovery: hereditary breast cancer, homologous recombination deficiency and PARP inhibitor | Po-Han Lin | Ching-Hung Lin |
| 17:10-17:40 | DDR science and early BRCA testing | Shani Paluch Shimon | Shin-Cheh Chen |
| 17:40-18:00 | Panel discussion | Luca Gianni/ Marc Thill/ Po-Han LinShani Paluch Shimon / Yuan-Ching ChangHuan-Ming Hsu / Wei-Pang Chung |

|  |
| --- |
| **2020 Taipei International Breast Cancer Symposium**7F, Taipei Nangang Exhibition Center, Hall 2 **Sun.**, November **8**, 2020 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| 07:50-08:40 | Abstract oral presentation | Ling-Ming Tseng |
| 08:40-09:00 | Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets | Chi-Cheng Huang | Ming-Feng Hou |
| 09:00-09:20 | Unique characteristics of breast cancer in East Asia | Yen-Shen Lu |
| 09:20-09:35 | 致詞/永齡華人抗癌聯盟簡介/頒感謝狀 | Ling-Ming Tseng |
| **Luminal ABC** |
| 09:35-09:40 | Case presentation, and vote  | Lo Chiao |
| 09:40-10:10 | Treatment choice in post CDK4/6 inhibitor era  | Naoto Ueno | Chiun-Sheng Huang |
| 10:10-10:40 | CDK4/6 inhibitor and immune modulation  | Shom Goel | Ming-Hsin Yeh |
| 10:40-11:00 | Coffee Break |
| 11:00-11:30 | Evolving evidence on the uniqueness of premenopausal breast cancer | Ching-Hung Lin | Dar-Ren Chen |
| 11:30-12:00 | Envision a longer future: uncover the new era of endocrine treatments in HR+ HER2- metastatic breast cancer | Ta-Chung Chao | Kun-Ming Rau |
| 12:00-12:20 | Panel discussion | Naoto Ueno / Shom Goel / Ching-Hung LinTa-Chung Chao / Ming-Yang WangShih-Che Shen / Chun-Yu Liu |
| 12:20-13:00 | Luncheon SymposiumNew developments in chemotherapy-based treatment for early breast cancer | Chin-Sheng Hung | Dah-Cherng Yeh |
| 13:00-13:20 | Break |
| **Special Lecture** |
| 13:20-13:50 | Artificial intelligence in breast cancer medicine | **Kung-Hao Liang** | Fiona Tsui-Fen ChengChao-Ming Hung |
| 13:50-14:20 | Clinical breast cancer practice during COVID-19 pandemic | Hsiu-Hsi Chen | King-Jen Chang Chen-Hsiang Chang |
| 14:20-14:50 | COVID19: ensuring the quality, resiliency, and continuity of breast cancer care during a pandemic | Chieh-Han Chuang | Fang-Ming ChenChin-Hua Tsai |
| 14:50-15:10 | Coffee Break |
| **Local Regional Therapy** |
| 15:10-15:30 | Lessons learned from nipple-sparing mastectomy with oncologic outcomes | Shin-Cheh Chen | Dar-Ren ChenYao-Lung Kuo |
| 15:30-15:50 | Locoregional Management after Neoadjuvant Chemotherapy | Jeong Eon Lee | Shih-Hsin TuChia-Ming Hsieh |
| 15:50-16:10 | Multidisciplinary management of locoregional recurrence | Jyh-Cherng Yu | Shou-Tung ChenHung-Wen Lai |
| 16:10-16:30 | Whole brain radiotherapy for breast cancer patients with brain metastases: The role of hippocampal avoidance | Wen-Chi Yang | Cheng-Ying ShiauHong-Tai Chang |
| 16:30-16:50 | Panel discussion | Shin-Cheh Chen / Jeong Eon LeeJyh-Cherng Yu / Wen-Chi YangFrank Fu Ou-Yang / Kuo-Ting Lee / Kuo-Hsiu Liao |
| 16:50-17:00 | Award Ceremony & Closing | Ling-Ming Tseng |